Please login to the form below

Not currently logged in
Email:
Password:

Melior enters new pharmaceutical collaboration

Melior Discovery signs an agreement with Johnson & Johnson Pharmaceutical Research & Development for use of Melior's proprietary theraTRACE indications discovery platform to identify new indications

US-based drug discovery company Melior Discovery has signed an agreement with Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) for use of Melior's proprietary theraTRACE indications discovery platform to identify new indications for multiple J&JPRD drug candidates.

Financial terms were not disclosed.

Melior's theraTRACE platform is a multiplexed set of integrated in-vivo models which quickly identify previously unknown applications for pharmaceutical compounds. It can be applied to discovery, development stage and marketed agents and has already identified novel indications for a number of development stage drugs.

Dr Andrew Reaume, president and CEO of Melior, said of the agreement: "Our theraTRACE indications discovery platform is already proving its value in our existing collaborations with Merck and Pfizer, as well as in screening for our own drug development efforts. We are delighted to be working with J&JPRD, and we look forward to a productive collaboration."

7th August 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...

Infographics